Related Experiment Videos
Low molecular weight heparin in acute stroke
1Division of Stroke Medicine, University of Nottingham, University Hospital, Queen's Medical Centre, Nottingham, NG7 2UH, UK. philip.bath@nottingham.ac.uk
Expert Opinion on Investigational Drugs
|July 5, 2005
Summary
Low molecular weight heparins (LMWHs) may offer benefits in acute ischaemic stroke, but evidence is unclear. A systematic review is needed to assess their safety and efficacy in stroke patients.
Area of Science:
- Neurology
- Pharmacology
- Thrombosis Research
Background:
- Acute ischaemic stroke management involves reperfusion, preventing clot extension, and neuroprotection.
- Heparins, including low molecular weight heparins (LMWHs), are effective in venous thromboembolic disease and coronary artery disease.
- The efficacy and safety of LMWHs in acute ischaemic stroke remain uncertain.
Purpose of the Study:
- To systematically review the safety and efficacy of low molecular weight heparins (LMWHs) in acute ischaemic stroke.
Main Methods:
- A systematic review of Phase II and III clinical trials assessing LMWH in acute ischaemic stroke was conducted.
- Data on efficacy (stroke outcomes) and safety (intracranial hemorrhage) were analyzed.
Main Results:
- Unfractionated heparin showed no overall benefit and increased intracranial hemorrhage in a large trial.
- LMWHs have demonstrated effectiveness in preventing deep vein thrombosis (DVT) and pulmonary embolism (PE).
- Current evidence on LMWH efficacy and safety specifically for acute ischaemic stroke is inconclusive.
Conclusions:
- Further systematic review is required to definitively assess the role of LMWHs in acute ischaemic stroke treatment.
- While LMWHs reduce DVT and PE risk, their net benefit in stroke requires clarification.
- The potential risks, such as intracranial hemorrhage, must be carefully weighed against benefits.